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Resumo 
Doenças mitocondriais, envolvendo disfunções na cadeia cytochromo, estão 
geralmente associadas com bloqueios a nível do COX, causando disfunções 
metabólicas e em alguns casos morte. 
O uso de tabaco e exposição a fumos tóxicos causam milhões de mortes por ano 
(segundo a WHO) devido aos seus efeitos adversos em viabilidade celular, e estão 
associados a muitas doenças respiratórias. Dos 5000 compostos do fumo de cigarros, 
o cianeto e monóxido de carbono são os mais proeminentes inibidores do COX. 
O objetivo primário deste estudo era gerar uma proteína AOX cataliticamente 
ativa para transfectar células de mamíferos, com potencial farmacológico para 
compensar deficiências do COX. O objetivo secundário era testar a hipótese de que a 
expressão de AOX, uma oxidase alternativa ausente nos vertebrados, consegue 
proteger as células até um certo ponto, do dano causado por fumos tóxicos. Para os 
objetivos propostos, (1) uma proteína recombinante AOX foi gerada, em sistema de 
expressão de proteínas recombinantes em procariotas, em conjugação da AOX com um 
péptido TAT, derivado do vírus de imunodeficiência humana que permite a penetração 
através de membranas de proteínas a ele conjugadas; e (2) a resposta à exposição a 
CSE foi analisada e comparada em três linhas celulares diferentes expressando AOX e 
os seus respetivos controlos WT (293T HEK, MEF e NIH 3T3). 
A produção e purificação de uma proteína recombinante membranar é uma 
tarefa exigente e complexa. Apesar de não ter sido possível obter uma proteína AOX 
ultra pura, este trabalho forneceu evidências de a AOX recombinante foi incorporada 
por células de mamíferos, onde demonstrou atividade catalítica tanto in vitro e ex vivo. 
Contrariamente a hipótese inicial, células com expressão de AOX não foram protegidas 
dos efeitos tóxicos causados por exposição a CSE. Tanto, a proliferação como o número 
de células viáveis foi reduzido na mesma proporção em células AOX e células controlo. 
O objetivo principal de estabelecer um protocolo para produzir e purificar uma 
AOX cataliticamente ativa foi alcançado com sucesso. Será interessante verificar se a 
TAT-AOX poderá ser usada para tratamento em modelos in vitro, ex vivo e 
eventualmente in vivo, de doenças mitocondriais. Quanto ao objetivo secundário, tendo 
em conta os resultados obtidos neste trabalho não se pode concluir que a AOX confere 
proteção contra fumos tóxicos, porém é preciso considerar que existem diferenças entre 
a composição do CSE e dos fumos tóxicos. Portanto, são necessários mais estudos 
compreensivos usando exposição direta a fumo de cigarro ou métodos de extração de 
toxinas alternativos. Palavras-chave: oxidase alternativa (AOX), extrato de fumo de 
cigarro (CSE), , HIV-derivado transactivador da transcrição, hipoxia, fumo de cigarro. 
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Summary 
Mitochondrial diseases involving dysfunctions in the cytochrome chain, are 
generally associated with blockades at level of COX, causing metabolic dysfunctions and 
in some cases death.  
Tobacco use and exposure to toxic smoke causes  millions of deaths per year 
(according to the WHO) due to its adverse effects on cell viability and it is associated 
with many respiratory diseases. Among the 5000 compounds of the cigarette smoke, 
cyanide and carbon monoxide are the most prominent inhibitors of COX. 
The primary goal of this study was to generate a catalytically active AOX protein 
to transfect mammalian cells, with the pharmacological potential to compensate for COX 
deficiencies. The secondary goal was to test the hypothesis that expression of AOX, an 
alternative oxidase absent in vertebrates, can protect cells to some extent against toxic 
smoke damage. To achieve the proposed goals, (1) a recombinant AOX protein, in a 
prokaryotic recombinant protein expression system with AOX being conjugated to a TAT  
peptide, was generated, TAT is derived from the human immunodeficiency virus and 
enables cell membrane penetration of the conjugate; and (2) the response of three 
different AOX-expressing cell lines and their respective WT controls (293T HEK, MEF 
and NIH 3T3) to CSE was analysed and compared.  
Producing and purifying a recombinant membrane protein is complex and 
challenging. Despite not being able to generate a highly purified AOX protein, this work 
provided evidence that the recombinant AOX was taken up by mammalian cells, where 
it was catalytically active in vitro and ex vivo. Unlike the initial hypothesis, AOX-
expressing cells were not protected from toxic effects provoked by exposure to CSE. 
Both, viable cell number and proliferation were reduced to the same degree in AOX and 
control cells. 
The primary goal to establish a protocol to produce and purify a catalytically active 
AOX protein was fully reached. It will be interesting to see if TAT-AOX treatment can be 
used in vitro, ex vivo and, eventually, in vivo in different disease models with 
mitochondrial impairment. Regarding the secondary goal, from the results obtained in 
this work it cannot be conclude that AOX confers protection against toxic smoke, 
however one has to take into account that CSE and CS contents differ. Therefore, more 
comprehensive studies are needed using direct cigarette smoke exposure or alternative 
toxin extraction methods. 
 
Key words: alternative oxidase (AOX), cigarette smoke extract (CSE), HIV-
derived transactivator of transcription, hypoxia, cigarette smoke. 
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1- Introduction 
  
Many species, but not mammals, harbour enzymes with the ability to branch the 
classical respiratory chain, e.g. alternative oxidase (AOX), which is a non-proton motive, 
inner mitochondrial membrane protein. AOX transfers electrons directly from ubiquinol 
(QH2) to oxygen thereby preventing reactive oxygen species (ROS) overproduction 
when complexes III or IV of the respiratory chain are blocked(1, 2). Due to its low affinity 
to QH2, as compared to complex III, AOX is catalytically active only under conditions 
when the cytochrome part of the respiratory chain (complex III and IV) is disabled, thus 
not interfering with the mitochondrial adenosine-tri-phosphate (ATP)  production under 
unstressed conditions(2). 
Due to its characteristics, Ciona intestinalis AOX has been used as a tool to 
compensate mitochondrial dysfunctions related to the respiratory chain and study 
disease etiologies. The results obtained so far give evidence that AOX can compensate 
for cytochrome c oxidase (COX) deficiencies in mammalian cells in vitro(3, 4) and flies 
in vivo. Furthermore, it is clear that a lack of ATP production is only one reason for 
cellular dysfunction. As important seems to be the ability of AOX to minimize oxidative 
damage by stopping the excess production of mitochondrial ROS(5, 6), to keep the 
tricarboxylic acid (TCA) cycle functional as well as conferring resistance to respiratory 
inhibitors(7).  
Toxic smoke and exposure to cigarette smoke (CS), is one of the biggest 
threats to public health. According to the World Health Organization (WHO), 6 million 
deaths per year worldwide are attributed to smoking(8). It is widely accepted that smoking 
can cause chronic lung diseases such as cancer, emphysema, and chronic obstructive 
pulmonary disease (COPD) among others(9, 10). Many of these diseases are associated 
with inflammation and oxidative stress in the pulmonary tissue. 
From the more than 5000 components present in the CS, many have already 
been identified as carcinogenic and hazardous (11). The oxidative stress caused 
by smoke in the lung tissues, is mainly associated with the ability of some smoke 
compounds to interact with and inhibit the mitochondrial respiratory chain (RC) 
complexes(12) and a decrease in the concentration of anti-oxidant enzymes(13). These 
conditions lead to an increase in the production of reactive oxygen species (ROS) (14) 
and  its accumulation inside the cells as well as hydrolysis of ATP in order to maintain 
the mitochondrial membrane potential. The most potent inhibitors of the respiratory chain 
in CS are cyanide(11) and carbon monoxide(15, 16), both inhibit COX. 
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In this work it was speculated that AOX could be used as a therapeutic to reduce 
or prevent damage caused by toxic smoke exposure. This hypothesis has been 
thoroughly tested in vitro by exposing different mammalian cell lines to cigarette smoke 
extract (CSE). More importantly, we aimed at the purification of a recombinant, 
catalytically active AOX protein.  
In the following section a bibliographic survey will be presented, regarding 
mitochondrial energy and ROS production, the hazards of CS, as well as an overview on 
AOX in general and a brief state of the  HIV-derived transactivator of transcription (TAT) 
protein. 
 
1.1- Mitochondria: energy and ROS production 
Mitochondria are one of the most metabolic active organelles in the cell; one 
major role is to synthesize ATP by oxidative phosphorylation. However they also are 
thermogenic, which is due to the energy dissipation in the form of heat during the ATP 
production, e.g. under low temperature conditions mitochondria can favour energy 
dissipation, thereby increasing heat production(17). Furthermore, mitochondria harbour 
important metabolic circuits and regulate cellular ion homeostasis, e.g. by buffering Ca2+ 
to control its available in the cytoplasm(18). Recently, several articles have been published 
highlighting the role of mitochondria in cell signalling(19-21). Mitochondria are shown to 
initiate different pathways such as the programed cell death (apoptosis), an important 
process to eliminate damaged or infected cells, with cytosolic Ca2+ being the signal for 
mitochondrial membrane permeabilisation and release of pro-apoptotic proteins(19, 20); or 
autophagy, a process that involves the digestion and recycling of biomolecules to prevent 
cellular dysfunctions. Mitochondria provide membranes for the formation of 
autophagosomes thereby also regulating mitophagy to turnover dysfunctional 
organelles, e.g. those damaged by ROS(19, 22). 
 
1.1.1- Energy production and substrates 
Production of ATP is one of the most important metabolic processes in a cell. 
Without ATP, cells would not be viable and would eventually die. ATP is the universal 
energy carrier produced by the breakdown of covalent ligations between molecules; the 
energy released from the break of the ligation is used to phosphorylate adenosine-di-
phosphate (ADP) giving rise to ATP(23). In mammalian cells two major processes produce 
ATP: (1) glycolysis in the cytosol of the cell and (2) oxidative phosphorylation (OXPHOS) 
in the mitochondrial matrix (aerobic respiration). 
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Glycolysis is the process of oxidizing sugar molecules to produce ATP. In this 
process a six carbon molecule (glucose) is broken down to two tri-carbon molecules 
(pyruvate), with a net yield of two ATP molecules and two molecules of nicotinamide 
adenosine dinucleotide (NADH)(23). 
In normoxia, the pyruvate will be used for aerobic respiration. In this process the 
pyruvate will be imported to the mitochondrial matrix where it enters the TCA cycle. A 
series of conversions and oxidative reactions produces high-energy electrons that will 
be carried as NADH and flavin adenosine dinucleotide (FADH2) to the inner membrane’s 
respiratory chain (RC). In the RC the electrons will be transported along the protein 
complexes, through oxidative reactions with oxygen being the final electron acceptor. To 
create an electrochemical gradient the flow of electrons is coupled with the pumping of 
protons from the mitochondrial matrix to the intermembrane space (IS) (mitochondrial 
membrane potential). Thus mitochondrial respiration generates a proton driven potential 
that is used by the F1F0 ATP synthase to phosphorylate ADP to generate ATP(24). 
It has been shown that under different culture conditions cells can adapt their 
metabolism and ATP production. This phenomenon can be facilitated to study 
mitochondrial functions, e.g. when grown in high concentrations of glucose, cells favour 
glycolysis over OXPHOS causing a decrease in the mitochondrial activity(25). Contrary, 
under glucose starvation or replacement with glutamine or galactose, cells rely more on 
oxidative phosphorylation for ATP production(25-27). Galactose is a glucose isomer that 
needs to be converted to glucose before it can be used as a substrate, this conversion 
consumes ATP and therefore yields no ATP production by glycolysis forcing the cells to 
compensate by increasing the yield of the OXPPHOS pathway(25). In contrast, glutamine 
is used directly in the TCA cycle as an alternative substrate to pyruvate(26), bypassing 
the glycolysis pathway. 
 
1.1.2- Respiratory chain and electron flow 
The electron transfer chain (ETC) is located in the inner mitochondrial membrane 
and is the major part of the RC. Its role is to transfer electrons from substrates originated 
in the TCA (NADH, FADH2) to oxygen. The ETC consists of four complexes in which 
three (complexes I, III, IV) are proton pumps. Complex II is an electron entry point. All 
complexes are integral membrane proteins that contain metal ions at their centre, such 
as iron or copper, and the oxidative potential of the complexes is such that a 
unidirectional flow of electrons along the chain is ensured among the complexes(24). 
The first complex is the NADH dehydrogenase (complex I). This complex accepts 
electrons from NADH and transfers them to the ubiquinone, with the pumping of four 
protons to the intermembrane space (IS) of the mitochondria(28).  
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The succinate:ubiquinone oxidoreductase (complex II) is the only respiratory 
complex that is not proton pumping. It accepts electrons from the FADH2, originating 
from succinate oxidation and also transfers the electrons to ubiquinone(28). 
Ubiquinone function in the RC is to accept electrons (becoming QH2) from the 
complexes I and II and transfer them to the Q-cytochrome c oxidoreductase (complex 
III)(28). Complex III is a less effective proton pump than complex I. It pumps two proton to 
the IS upon receiving and transferring the electrons from QH2 to oxidized cytochrome c 
(Cyt c)(28). However, as complex III can only transfer one electron at a time to Cyt c, an 
intermediary process, named Q-cycle(29) is needed. In this cycle, both a QH2 molecule 
and a ubiquinone molecule will bind to different sites of complex III. The QH2 molecule 
bound to the complex III Q-site will transfer one of its electrons to Cyt c, with the pumping 
of two protons to the IS associated with this step. The other electron will be transferred 
to the bound ubiquinone, giving rise to a semiquinone, giving the instability of the 
semiquinone another QH2 is needed to complete the cycle. Therefore the former QH2 
will return to the Q-pool as a ubiquinone, while another QH2 molecule will bind to the Q-
site and transfer one of its electrons to Cyt c and the other to the semiquinone, giving 
rise to an oxidized ubiquinone. This oxidized ubiquinone will bind to two protons from the 
mitochondrial matrix becoming QH2 and re-entering the Q-cycle. 
Cyt c transfers its electrons to COX (complex IV), which is also a proton pump, 
and transfers the received electrons to the molecular oxygen. The reduced oxygen will 
interact with two free protons in the matrix giving rise to one water molecule and finalizing 
the electron transfer(28). 
The last complex in the RC is the ATP synthase (complex V). This complex uses 
the proton driven force generated by ETC to synthetize ATP, by enabling the influx of 
protons from the IS to the matrix(28). Under low O2 levels (ischemia/hypoxia) conditions 
the ATP synthase can be partially reversed leading to a hydrolysis of ATP coupled to 
outward pumping of protons in order to retain the mitochondrial membrane potential(30), 
and to avoid excess ROS production(30). 
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Figure 1 Schematic of the respiratory chain. Electron flow is represented by the red arrows. 
 
1.1.3- ROS production 
The term ROS is used to describe a group of O2 derived radicals (O2-, H2O2 and 
OH•) that are able to interact with and damage the cell biomolecules. Superoxide (O2-) is 
the precursor of the hydrogen peroxide (H2O2) and hydroxyl anion (OH•), and the major 
organelle involved in its production in mammalian cells is the mitochondrion.  
Under normal conditions small amounts of ROS are produced by electrons 
leaking from the ETC to O2, however no damage is done to the cell due to the presence 
of anti-oxidant enzymes(31). Oxidative damage occurs when the ROS production is 
greater than the amount of ROS that the anti-oxidant enzymes can neutralize. 
Inside the mitochondria eight factors have been identified that contribute to ROS 
production(32), however only complex I and III are considered to be major ROS producers. 
Complex I can produce ROS by direct and indirect electron flow, in both cases 
the ratio of NADH/NAD+ and the reduce state of the Q-pool plays a crucial role in the 
amount of ROS produced. Under direct electron flow when the RC is reduced, and 
therefore the Q-pool becomes highly reduced, the electrons coming from the NADH will 
not be transferred to ubiquinone and will leak to the O2 in the matrix creating O2-(33). This 
Matrix 
Intermembrane space 
Cytosol 
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situation can be caused by mutations, dysfunctions or inhibitors of the RC which disables 
the electron transfer from complex IV to O2 increasing the reduction state of the Q-
pool(14). Complex I is rotenone sensitive and in the presence of this inhibitor the electrons 
from NAPDH will be leaked from complex I to O2 generating excess amounts of ROS. 
When complexes III or IV are inhibited, electrons can flow from complex II to complex I, 
a phenomenon called reverse electron flow. This causes a leak of electrons from 
complex I directly to O2 as well as an increase in the NADH/NAD+ ratio, which favours 
ROS production in the IS(14). 
Complex III produces large amounts of ROS in the presence of its inhibitor 
antimycin A (AMA). This causes a transfer of electrons from the Q-cycle to O2, generating 
ROS in both the mitochondrial matrix and IS. In the absence of inhibitors, the ROS 
production by complex III is minimal when compared to the amounts produced by 
complex I(14). 
 
1.2- Tobacco: lethality and hazards to health 
Tobacco is a legal drugs that kills people when used according to its purpose. 
Around the globe smoking kills more than five million people by direct smoking and six 
hundred thousand by second hand smoking, per year and if the smoking trend does not 
change, around eight million people per year around the globe are estimated to die by 
2025. Furthermore, the deaths annually attributed to smoking are superior to the 
combined deaths per year of tuberculosis, HIV/AIDS and malaria(34). The use of tobacco 
is a risk factor in 6 of the 8 leading diseases in the world, significantly contributing to 
respiratory diseases such as COPD and cancer in the respiratory tracks (Figure 2). 
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Figure 2 Graph of tobacco usage risk factor in 6 of the 8 leading causes of death in the world. Attached areas are the 
amount of death corresponding to tobacco usage in each disease. Adapted from “WHO Report on the global tobacco 
epidemic, 2008. 
Many of the CS components are hazardous to health, Talhout and co-workers 
published a list of 98 hazards components in CS with their respective endpoints(11). 
Although the mechanism and pathways by which CS harms the cell are not yet fully 
understood, the impact of smoking on health is very well established. Knowing that CS 
contains cyanide, and to a lesser degree carbon monoxide, an inhibition of complex IV 
is likely, leading to mitochondrial damage. 
It is known that CS damage is in part mediated by mitochondria as shown by Li 
et al. (2014) work, which shown that it was possible to attenuate CS damage by 
transferring mitochondria from stem cells epithelial airway cells(35). 
CS causes inflammation and increases oxidative stress, both in in vivo and in 
vitro models(9). Even short term CS exposure is enough to cause significant changes in 
in alveolar cells metabolism(12). Furthermore, CS inhibits complexes of the RC, thereby 
decreasing the levels of ATP and increasing the intracellular ROS concentration, causing 
mitochondrial fission impairment (13) and a metabolic shift from apoptosis to necrosis in 
lung cells(36). 
 
1.3- Alternative oxidase (AOX) 
Mitochondrial dysfunctions and especially blockades in the RC are almost always 
lethal. To cope with such dysfunctions some organisms have developed mechanisms or 
alternative pathways which are able to overcome these metabolic dysfunctions and limit 
ROS overproduction in the mitochondria. One such way is to bypass the blocked 
complex of the RC preventing the back-flow of electrons that would escape and generate 
ROS. 
Such a bypass system has evolved in plants, many microorganisms and 
metazoan. They counteract RC inhibition, especially complex III and IV, with the 
presence of a cyanide resistant AOX(37), in their RC. AOX is a mitochondrial inner 
membrane protein that transfers electrons from QH2 directly to O2, thus enabling a 
bypass of the cytochrome part of the RC(38) allowing the organism expressing it to cope 
with mitochondrial blockades in the cytochrome chain. 
 
1.3.1- Function on native systems 
In plants a natural and unavoidable mitochondrial blockade happens daily caused 
by the presence of sunlight. During photosynthesis the majority of ADP is directed to 
chloroplast and the intracellular ATP levels increase, in such conditions, the 
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mitochondrial membrane potential decreases and oxidation of substrate is almost 
stopped, therefore any electrons entering the RC would easily be leaked and generate 
ROS (39). 
AOX plays an important role in keeping the mitochondrial metabolism active(40), 
which is essential to plants as some metabolic reactions only happen in the mitochondria. 
Since it enables the transfer of electrons from the reduced Q-pool of the RC to O2 it 
assures the maintenance of a membrane potential as well as the availability of NAD+ to 
other metabolic cycles, e.g. the TCA cycle. AOX has a very low affinity to QH2 compared 
to complex III, therefore it cannot overtake the bypass mechanism under normal 
conditions. Thus, AOX is functionally active only when the Q-pool is highly reduced (41, 
42). 
 
1.3.2- Ciona intestinalis AOX in human health 
With the current advance in molecular biology it is easy to integrate a foreign 
gene into the mammalian genome. AOX has a wide expression in the lower organism, 
plants and some animal phyla(37), however for some reason it is absent in the mammals. 
Nonetheless, its expression in some animal phyla provides a pathway of expressing AOX 
in human cells, since the phylogenetic proximity of the phyla increase the chance of 
successfully expressing a catalytically active AOX in a heterologous system. Therefore, 
taking into account that AOX could be a potential cure for some mitochondrial diseases 
in mammals, provided all the reasons to engineer AOX mammalian cells.  
Ciona intestinalis is the closest species to chordates harbouring AOX protein. In 
terms of structure it resembles AOX proteins in other species, possessing a di-iron 
centre, however in comparison to the widely used Trypanosoma AOX it possesses two 
highly positive charged loops (Figure 3). Ciona intestinalis AOX, was successfully used 
by Hakkaart et al. (2006) to produce stable AOX human cell lines resistant to cyanide(7). 
This pioneering work opened the path for testing the possibility of AOX to rescue 
mitochondrial dysfunctions. Furthermore, AOX can be a possible treatment for 
mitochondrial diseases, since a wide spectrum of diseases ranging from encephalo-
myopathy and cardiomyopathy in early childhood to neurodegenerative disease in the 
elderly are associated with complex IV deficiencies(39) and there are currently no known 
treatments available.  
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Figure 3 Structural 3D model of Ciona intestinalis AOX (green) subunit using Trypanosomal AOX as a template for 
homology modelling (orange) with di-iron centre, deletion and elongation loops annotated. Model designed by Liliya 
Euro 
 
1.4- TAT protein 
An effective protein delivery to and correct intracellular targeting in eukaryotic 
cells has great impact on medical treatments and molecular studies. The discovery that 
HIV-1 TAT protein could cross almost every eukaryotic cell membrane, including the 
nuclear membrane, when added to the culture medium(43, 44) was the first step to test if 
fusion of TAT to a recombinant proteins would allow its efficient transfection. Further 
studies showed the existence of a protein transduction domain (PTD) in the TAT protein 
was responsible for the ability of crossing the cellular membranes by a not yet 
understood mechanism which is independent of receptor, transporter or endocytosis(45, 
46). These findings supported the development of applications of an intracellular delivery 
system(47), which have been used in molecular studies, in particular to deliver an 
alternative respiratory chain enzyme Ndi1(48) in vivo to rat heart after ischemia-
reperfusion(49, 50). 
 
Di-iron centre 
Deletion loop 
Elongation loop 
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1.5- Goal 
The goal of this work was to generate a recombinant AOX protein purified in 
heterologous systems that can be used as a transfectant to rescue mammalian cells 
exposed to toxins. Furthermore, it was also aimed to test if AOX could be used as a 
therapeutic to reduce or prevent cellular damage caused by exposure to CSE as a 
makeshift of cigarette smoke. We tested the susceptibility of cells expressing AOX to 
CSE in varying growth mediums. Therefore, the work was structured into two separate 
projects: 
 
 
1. To test the production and purification of a catalytically active AOX in 
heterologous systems, and its delivery to mammalian cells.  
 
2. To test that AOX expression is able to confer some degree of 
protection to CSE damage in mammalian cells. 
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2- Methods 
 
In order to achieve the goals of this project, both the concepts were tested 
separately.  
1. Production of AOX protein in heterologous expression systems, 
Escherichia coli BL21 (DE3) and Rosetta 2, followed by purification 
using affinity chromatography. 
2. Analysing the effect of CSE to induce physiological response in cell 
lines with and without AOX expression.  
 
2.1- Production of catalytically active recombinant AOX 
 
2.1.1- Plasmid engineering 
Plasmids for the generation of recombinant AOX were designed as follows: a 
SUMO(51) protein sequence  was fused upstream to the Ciona intestinalis AOX sequence 
(SUMO-AOX) with the pET30(52) vector (containing a HIS tag) as backbone (Champion 
pET Sumo expression, Thermo Fisher). Control plasmid was generated with a 
catalytically inactive (due a single a point mutation) AOX sequence. A second set of 
plasmids was engineered in the same way, which had an additional TAT(47) protein 
upstream of the AOX sequence and downstream of the SUMO protein sequence 
(SUMO-TAT-AOX). Restriction enzyme digest and Sanger sequencing were used to 
validate all the generated plasmids. 
 
2.1.2- Bacterial transformation 
Bacterial strains optimized for recombinant protein expression, such as 
Escherichia coli BL21 (DE3) one shot cells (Life Technologies) and Rosetta 2 were 
transformed using the engineered plasmids.  
One vial of E. coli BL21 (DE3) was thawed on ice, followed by addition of 5 ng of 
plasmid deoxyribonucleic acid (DNA) and incubated on ice for 30 min. Sample were 
heated to 42 °C for 30 s (heat shock) and immediately transferred to ice followed by 
addition of 250 mL Luria-Broth (LB) growth medium and incubation at 37 °C with 200 
rpm shaking for 1 h. Sample was transferred to 10 mL LB medium (Life Technologies) 
with kanamycin (50 µg/mL) and incubated overnight 37 °C with 200 rpm . 
One vial of chemically competent E. coli Rosetta 2 were thawed on ice and ice 
cold transformation reaction composed of 10 µl 5x KCM (500 mM KCl, 150 mM CaCl2 
and 250 mM MgCl2), 35 µl of sterile H20 and 5ng plasmid DNA was added. Sample 
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mixture was incubated on ice for 20 min followed by 10 min incubation at room 
temperature, after which, 1 mL of LB medium was added followed by an incubation at 
37 °C with 200 rpm shaking for 1h. Entire sample was inoculated in 10 mL of LB medium 
(Life Technologies) with kanamycin (50 µg/mL) and incubated overnight. 
 
2.1.3- Recombinant protein induction 
Culture conditions (growth temperature, concentration of isopropyl-beta-D-
thiogalactopyranoside (IPTG), addition of glucose and presence of iron salts in the 
culture) were evaluated to determine the optimal conditions for high protein yield. 
Analysis of recombinant protein production was done quantitatively using SDS-PAGE 
(stained by Comassie Blue) and ChemiDoc imaging software (Biorad). 
Different temperatures including room temperature (18 °C), 30 °C and 37 °C, 
were used to grow transfected E. coli. Supplementation with glucose to a concentration 
of 1% (w/v) in the medium was also tested. 
Protein solubilisation from the membranes was also tested with the use of 
dodecylmaltoside (DDM) at controlled amounts. 
 
2.1.4- Protein Purification 
Purification of SUMO-TAT-AOX was processed in collaboration with Liliya Euro 
from the University of Helsinki.  
Recombinant protein purification was achieved by cell lysis followed by harvesting 
the soluble fraction. The obtained protein extracts were diluted in starting buffer 
(20 mM NaH2PO4, 500 mM NaCl and 20 mM Imidazole) and purified by affinity 
chromatography. 
Briefly, a HIS trap F crude 5 mL (Life Technologies) was used to separate the 
recombinant protein from the rest of the extracts, resulting sample from the passing of 
the extract in starting buffer through the column was collected and labelled flow through 
(FT). Column was washed with 70 mM imidazole starting buffer, resulting sample from 
the wash was collected and labelled Fraction 1. A second wash of the column was 
performed with 200 mM imidazole starting buffer, resulting sample from the wash was 
collected and labelled Fraction 2. Purified recombinant protein was submitted to a 
process of desalting, using concentration columns (Vivaspin, Sartorious), by replacing 
the buffer ( 20 mM NaH2PO4, and 40 mM Imidazole). Separation of the SUMO from the 
recombinant AOX was performed using a SUMO protease (Life Technologies) according 
to the manufacturer’s instructions.  
A second purification was performed to separate the recombinant protein from 
the non-cleaved form and soluble SUMO protein. In summary, the cleavage product was 
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resuspended in starting buffer and passed through HIS trap F crude 5 mL, resulting 
sample from the passing of the cleavage product in starting buffer through the column 
was collected and labelled TAT-AOX. Column was washed with 200 mM imidazole 
starting buffer, resulting sample from the wash was collected and labelled SUMO. 
All samples were analysed qualitatively by Western blot using an anti-AOX 
antibody, and quantitative by SDS-PAGE (stained by Comassie Blue)and ChemiDoc 
imaging software (Biorad). 
 
Figure 4 Scheme of protein purification 
 
Figure 5 Scheme of SUMO cleavage and second TAT AOX purification 
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2.1.5- Recombinant AOX activity 
Recombinant TAT-AOX protein activity was evaluated by AMA (Sigma Aldrich) 
resistance selection. Briefly, 3T3 WT cells were seeded in 24-well plates and let grown 
until 60% confluency was reached.  Growth medium was removed and the well was filled, 
up to one sixth of its total volume, with growth medium with 0.027 µg/µL of recombinant 
protein. Plates were incubated for 1 h at 37 °C, followed by addition of medium up to half 
of the volume of the well and incubated for 3 h. AMA was added to a concentration of 
100 µM and incubated for 48 h. Protein activity was determined by the presence and 
number of living cells in the culture in comparison with controls (3T3 WT and 3T3 AOX 
in the same conditions). 
Complementary ex vivo assays were done by Natascha Sommer in Giessen 
(Germany) using the perfused lung from littermate wild type (WT) with simulation of 
hypoxia, and measuring the variation in the pulmonary arterial pressure (PAP) when the 
lung was submitted to hypoxia and perfused with physiological buffers containing 
recombinant AOX protein. Controls were lungs from AoxRosa26 and WT littermates. 
 
2.2- AOX protection against CSE damage 
 
2.2.1- Cell lines 
Mouse embryonic fibroblast cells (MEFs) were isolated, by Praven Kumar 
(University of Helsinki), from embryos expressing AOX and their WT littermate as a 
negative control. Immunostaining confirmed expression of AOX. Primary cells were 
immortalized using a recombinant lentiviral vector(53). 
Eric Dufour (University of Tampere) generated 293T Human Embryonic Kidney 
cells (HEK) and NIH 3T3 fibroblast expressing AOX or GFP as described by Hakkaart et 
al. (2006)(7). Briefly, the cells were virus transfected using an AOX vector with a green 
fluorescent protein (GFP) marker, positive transfection was evaluated by GFP detection 
using a fluorescence microscopy. All cell lines used were tested for AOX expression by 
Western blot using a specific AOX antibody.  
 
2.2.2- CSE production 
CSE was produced by bubbling smoke of a research cigarette(54) (3R4F, 0.7 mg 
nicotine and 9.5 mg tar, University of Kentucky Tobacco Research and Development 
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Centre), through 10 mL of cell growth medium using a peristaltic pump (Langer 
Instruments) for suction. The cigarette was smoked within 1 min. The CSE (stock) was 
then filter-sterilized using a 0.22 µm nylon filter (Sigma Aldrich), followed by a quality 
control analysis by measuring the pH and OD at 320 nm for standardization (pH 7.4; 
OD320nm = 0.7). 
 
2.2.3- Cell counting and seeding 
Cells were grown in a 10 cm plate until reaching a 80% confluency, then 
trypsinised and pelleted in a 10 mL plastic vial by spinning at 800 rpm for 3 min. Pellet 
was re-suspended in 1 mL sterile PBS and counted using a Bürker chamber. Equal 
number of cells (25 000) was seeded into 24-well plate to ensure the same quality and 
quantity of cells on day of experiment. 
 
2.2.4- Plate-coating 
Coated plates were prepared by covering the bottom surface of the well with a 
coating agent, and incubated in a cell culture hood at room temperature for 30 min. 
Excess of coating agent was washed off using sterile 1X phosphate buffered saline (PBS). 
Two different coating agents, 5% (w/v) gelatine solution (Millipore) and 0.1% (w/v) 
polylysine solution (Life Technologies), were used to produce different coated plates. 
  
2.2.5- Growth mediums 
Different cell culture media were used to test different metabolic conditions: (a) 
Dulbecco's Modified Eagle's medium (DMEM) with high glucose (25 mM) (Lonza), ( b )  
DMEM with low glucose (5 mM) (Lonza) and ( c )  DMEM with galactose (10 mM) 
(Life technologies. Cell cultures were grown in an incubator chamber main ta ined at 
37 °C with a CO2 saturation level of 5%. 
Medium supplements used were 1x Glutamax (Life Technologies), 1x Penstrep 
(Life Technologies), Fetal Bovine Serum (FBS) (Life Technologies), 1mM sodium 
pyruvate (Sigma Aldrich) and Calf Bovine Serum (CBS) (ATCC), according to Table 1.  
  
FCUP 
Analyzing the AOX potential as a prevention treatment for cigarette smoke 
16 
 
 
 
Table 1 Details of medium supplements and serum concentration for each cell type used.  
DMEM SERUM SUPPLEMENTS CELL TYPE 
USED 
HIGH GLUCOSE 20% FBS Glutamax and Penstrep MEFs 
HIGH GLUCOSE 10% FBS Glutamax and Penstrep HEK 
HIGH GLUCOSE 10% CBS Glutamax and Penstrep 3T3 
LOW GLUCOSE 10% FBS Glutamax and Penstrep HEK  
LOW GLUCOSE 5% FBS Glutamax and Penstrep MEFs 
LOW GLUCOSE 10% CBS Glutamax and Penstrep 3T3 
GALACTOSE 20% FBS Sodium pyruvate and Penstrep MEFs 
GALACTOSE 10% FBS Sodium pyruvate and Penstrep HEK  
GALACTOSE 5% FBS Sodium pyruvate and Penstrep MEFs  
GALACTOSE 10% CBS Sodium pyruvate and Penstrep 3T3 
 
Galactose medium were not supplemented with glutamax since the medium 
formulation already contained glutamine. Sodium pyruvate supplementation was 
necessary in order to correlate the physiological response with the high and low glucose 
medium, which had a 1 mM concentration in their formulation. 
 
2.2.6- Exposure to CSE 
Cell cultures with a confluence between 60% were incubated with CSE at different 
concentrations (prepared by diluting the stock CSE with growth medium). Cells were 
incubated for 24h or 48h to measure the effect of toxins over time. 
 
2.2.7- Evaluation of response mechanisms 
Cell plates were analysed using a cell viability kit (Cell Counting Kit 8, Sigma 
Aldrich). Briefly, cells were washed with 1x PBS (Life Technologies) followed by 
incubation with Dulbecco`s Phosphate Buffered Saline (DPBS) medium (Life 
Technologies) with 2% (v/v) of reagent from the kit. Absorbance at 450 nm estimated 
the number of viable cells by using a calibration curve. Statistical correlation by ANOVA 
two-way test was used to evaluate the differences in the physiological response to CSE 
exposure between the AOX expressing cells and its controls.  
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3- Results  
 
3.1- Purification of catalytically active recombinant AOX 
 The first goal of this work was to produce and purify an active AOX in 
heterologous systems. To achieve this different approaches were used to increase the 
yield of AOX protein production in transformed bacteria. Soluble recombinant protein 
produced was purified and tested for integration and catalytic active in mammalian cells. 
 
3.1.1- Recombinant AOX production in bacteria 
Transformed bacteria E.coli BL21 showed to be viable and proliferative at 37 °C, 
with a slower growth rate in culture induced with addition of IPTG, comparatively to non-
induced cultures, thus suggesting that a metabolic extra burden, such as the 
recombinant AOX production, was slowing down their growth rate (Figures 4-1 and 5-1), 
such behaviour is common when inducing recombinant protein production in E.coli(55). 
Furthermore, SDS-Page analysis of different time points after induction provided 
evidence that recombinant AOX was actually being expressed, by the appearance of a 
band approximately 60 kDa in the induced culture, which was absent before induction 
(Figures 4-2 and 5-2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 SUMO AOX production analysis: growth monitoring by OD600 measurement in specific time points (1) and SDS-
Page analysis of samples harvested in specific time points with location of SUMO TAT-AOX (approximately 60 kDa) is 
highlighted in red box. (2) 
 
 
1 2 
FCUP 
Analyzing the AOX potential as a prevention treatment for cigarette smoke 
18 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 SUMO TAT-AOX production analysis: growth monitoring by OD600 measurement in specific time points (1) and 
SDS-Page analysis of samples harvested in specific time points with location of SUMO TAT-AOX (approximately 60 kDa) 
is highlighted in red box. (2).  
 
3.1.2- Increasing yield of protein in soluble form  
To increase the amount of protein in the soluble fraction, in order to simplify the 
extraction and purification from the bacterial culture, overnight growth in transformed 
E. coli BL21 (DE3) at room temperature (RT), 30 °C and 37 °C was analysed (Figure 6), 
to determine if by reducing the growth temperature, thus slowing down culture growth, 
to values bellow the optimal 37 °C, could increase the accumulation of soluble protein. It 
was possible to observe that the difference between the amount of protein in the soluble 
fraction and in the membrane fraction was smaller when cells were grown at 30 °C (ratio 
1:1.5) when compared to growth at RT (ratio 1:2.5) and 37 °C (ratio 1:2.4).  
 
 
Figure 8 SDS-Page of SUMO TAT-AOX production analysis of homogenate, membrane fraction and soluble fraction at 
different growth temperatures: room temperature (RT), 30 °C and 37 °C. Location of SUMO TAT-AOX (approximately 60 
kDa) is highlighted in red box. 
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In combination with decreasing the growth temperature to 30 °C, different 
strengths of protein induction were tested, by decreasing the concentration of the pET30 
system inducer (IPTG) in the growth medium. SDS-Page analysis showed that 
decreasing the IPTG concentration did not increase the yield of soluble protein (ratio 
1:1,5), furthermore IPTG induction with concentrations lower than 0.005 mM were not 
able to induce recombinant protein expression (Figure 7-1). Addition of glucose to the 
growth medium did not increase the yield of soluble protein, thus proving that the low 
yield was not due to a low expression of the protein by the promoter sequence in the 
plasmid(56) (Figure 7-2).  
 
 
 
 
 
 
 
 
 
 
Figure 9 SDS-Page of SUMO TAT-AOX production analysis of membrane fraction and soluble fraction at grown at 30 °C 
with different IPTG induction in LB with kanamycin (1) and LB 1% glucose with kanamycin (2). Location of SUMO TAT-
AOX (approximately 60 kDa) is highlighted in red box. 
 
Due to the low yield after the change in growth condition, solubilisation of the 
protein incorporated in the membrane fraction was performed using DDM. Solubilisation 
of the entire amount of protein was not achieved, however an increase in the amount of 
soluble protein (from 1:1.5 to 1:0.45, Figure 8) was observed, upon using a 
1.5% (w/v) DDM concentration. Despite the promising result one cannot overlook the 
fact that harsh solubilisation treatments, such as the one performed, can compromise 
the recombinant protein catalytic activity(57), thus rendering it useless for the delivering of 
a catalytically active protein to the cells. 
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Figure 10 SDS-Page of SUMO TAT-AOX analysis of membrane fraction and soluble fraction with protein solubilisation 
using different DDM concentrations. Location of SUMO TAT-AOX (approximately 60 kDa) is highlighted in red box. 
 
Since in E. coli BL21 (DE3) the accumulation of recombinant protein tended to 
be higher in the membrane fraction than in the soluble fraction, another E. coli strain was 
used for the protein production. By repeating the temperature and IPTG tests in 
transformed E. coli Rosetta 2, a shift in the distribution of the protein between the soluble 
fraction and the membrane fraction was achieved (from Figure 9), when grown overnight 
at 30 °C (ratio 1:1) in opposition to growing overnight at 37 °C (ratio 1:1.5) . 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 SDS-Page of SUMO TAT-AOX production analysis of homogenate, membrane fraction and soluble fraction at 
30 °C and 37 °C with 0,25mM IPTG and 0,025mM IPTG. Location of SUMO TAT-AOX surrounded at red. 
 
In order to understand why most of the protein was being incorporated into the 
membranes, despite the conjugation of SUMO protein, an analysis of the protein 
structure was performed. After obtaining a 3D structural model for the Ciona intestinalis 
AOX protein (designed by Liliya Euro), it was possible to identify the influence of the di-
iron II active centre.  
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Effect of iron salts supplementation was tested by performing a SDS-Page 
analysis of transformed E. coli Rosetta 2 grown at  30 °C with a 0.25 mM IPTG induction 
and with different concentrations of iron II (Fe2) and iron III (Fe3) supplementation in the 
growth medium, respectively. In both, Fe2 and Fe3 supplementation a clear increase of 
protein in the membrane fraction with the increase in iron concentration in the medium 
was achieved (Figure 10). 
 
 
 
 
 
 
 
 
 
Figure 12 SDS-Page of SUMO TAT-AOX production analysis of homogenate, membrane fraction and soluble fraction 
grown at 30 °C in LB kanamycin medium with iron II supplementation (1) and iron III supplementation (2). Location of 
SUMO TAT-AOX surrounded at red. 
 
 
3.1.3- Purification of recombinant AOX 
Purification of recombinant AOX from bacterial extract was performed by using a 
HIS trap affinity chromatography purification technique, which targeted the SUMO 
protein’s HIS tag. Despite being able to successfully target the recombinant protein 
(Figure 11), imidazole presence in the buffer seemed to be crucial to keep the protein 
soluble in order to perform the cleavage of the SUMO protein (Figure 12 and 13).  
 
 
 
 
 
 
 
 
 
 
Figure 13 Western blot of SUMO-TAT-AOX HIS trap affinity chromatography purification results. Red rectangles highlight 
locations of SUMO-TAT-AOX (approximate 60 kDa) and AOX (approximate 37 kDa) 
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Figure 14 Western blot of SUMO-TAT-AOX desalting and SUMO cleavage (cleaved) results. Red rectangles highlight 
locations of SUMO-TAT-AOX (approximate 60 kDa) and AOX (approximate 37 kDa) 
 
 
 
Figure 15 Western blot of SUMO-TAT-AOX purification protocol results, using imidazole in the desalting step (before 
cleavage) and attempting to purify TAT-AOX from the other proteins in the cleavage product. Red rectangles highlight 
locations of SUMO-TAT-AOX (approximate 60 kDa), TAT-AOX (approximate 40 kDa) and AOX (approximate 37 kDa).  
 
Although it was possible to produce an enriched TAT-AOX extract (containing the 
TAT-AOX, SUMO protein and other unidentified bacterial proteins), the production of a 
purified TAT-AOX extract proved to be challenging due to the loss of recombinant protein 
in the second purification, which was aimed to separate TAT-AOX from the other proteins 
in the extract. Nonetheless the enriched TAT-AOX extract was used to analyse the 
catalytic activity and cell delivery of the purified TAT-AOX. 
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3.1.4- Recombinant AOX activity 
In vitro assays to test the activity of the recombinant AOX were performed by 
adding enriched TAT-AOX extract to the growth medium of a 60% confluent NIH 3T3 cell 
plate and incubation for 3 h, followed by addition of 100 µM AMA and incubation for 48 
h at 37 °C. It was observed, both visually and quantitatively, that the culture exposed to 
the recombinant protein showed a significant difference in number of viable cells to the 
non-exposed culture (p<0.05, Figure 14 and 15). Furthermore, AMA resistance conferred 
by the addition of enriched TAT-AOX extract, correlated to the AMA resistance present 
in the AOX cell lines used as control. 
Cell proliferation in control conditions after exposure to TAT-AOX (visual 
observation of a culture with 90%confluence) was found to be much lower than in non-
exposed cells (over confluent), this significant difference in number of viable cells in 
controlled condition (p<0.05; Figure 15). Recombinant protein concentrations higher than 
0.027 µg/µL lead to the death of the entire culture, in a period less than 3 h. TAT-AOX 
transfection success (40%-50%), in exposed cells was visually estimated, with 
correlation to the ratio obtained in the quantification, by comparing the amount of viable 
cells after 48 h AMA incubation. In summary, there was evidence that the purified TAT-
AOX was active and incorporated into the cells, however the enriched TAT-AOX extract 
seemed to have certain degree of toxicity to mammalian cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 In vitro TAT-AOX activity results of AMA incubation in NIH 3T3 cell lines: wild type (WT), AOX and wild type 
with TAT-AOX diluted in growth medium (WT+TAT-AOX). Dead cells appear as round and bright cells. 
 
 
Control WT + TAT-AOX WT AOX Control Control 
WT + TAT-AOX WT AOX AMA AMA AMA 
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Figure 17 Results of NIH 3T3 WT and exposed to enriched TAT-AOX (TAT), incubated in DMEM with 100 µM AMA for 
48 h, in both number of thousands of viable cells (on the left) and ratio between live cells in tested condition and control 
condition with no AMA (on the right). Significance of the difference in the measured values is represented by the stars (*), 
the more stars represented the higher the significance 
 
 
Ex-vivo activity assays of the enriched TAT-AOX extract, were performed by 
Natascha Sommer’s laboratory (Giessen, Germany), using a WT perfused lung. To 
correlate any obtained results to the recombinant protein activity, the physiological 
response to hypoxia of perfused lungs of both WT and AOXrosa26 littermate mice were 
analysed to serve as a negative and positive control, respectively. It was reported that 
WT perfused lungs, had an elevated variation of PAP, under the first hypoxic challenge, 
which was attenuated by the increase of O2 concentration in the perfusion buffer 
(unpublished results).  Oppositely, AOX had a low variation of PAP under the first hypoxic 
challenge time points, which increased with the increased O2 concentration in the 
perfusion buffer up to an O2 concentration of 1:1000, followed by an attenuation of the 
variation of PAP with further increase O2 concentration (unpublished results). Both lungs 
used in the experiment showed similar physiological behaviour under perfused weighted 
(PW) normoxia and under hypoxia (HOX) conditions (unpublished results). Furthermore, 
both lungs were responsive to U46(58, 59) (pharmacological compound that induces 
vasoconstriction) induced hypoxia conditions, showing an elevated variation of PAP. 
Perfusion of a WT lung under HOX condition, with physiological buffer containing 
a dilution of the enriched TAT-AOX extract, achieved a nullification in hypoxia variation 
of PAP (Figure 16), which correlated to the physiological response of a perfused AOX 
lung. The used WT lung was responsive to U46 induced hypoxia conditions, by showing 
an elevated variation of PAP.  
N=2 
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Hypoxic pulmonary vasoconstriction is a self-regulatory mechanism, responsible 
for an increase in PAP value under low O2 availability (hypoxia) (60). Therefore, 
information regarding the lung response to HOX can be obtained by analysing the 
variation of PAP. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 Ex vivo TAT-AOX activity results of perfusion of a WT lung with TAT-AOX (point of perfusion indicated by 
arrow) in physiological buffer. This figure is shown with the permission of Natascha Sommer. 
 
 
3.2- AOX protection against CSE damage 
In order to investigate if AOX expression in the mitochondria’s respiratory chain 
could confer some degree of protection against damaged caused by CSE, physiological 
response of AOX transgenic cell lines to exposure of CSE dilutions for 24h and 48h 
respectively, was analysed. WTs of each cell line were used as a control. In the tested 
fibroblast cell lines, AOX and WT were identical with respect to cell morphology as well 
as growth rate. To favour different metabolic conditions, different DMEM media were 
used. After exposure, the numbers of viable cells were quantified and normalized using 
a ratio of the number of viable cells in the tested CSE dilution to the number of viable 
cells in a control condition (same exposure time in growth medium without CSE). 
 
3.2.1- 293T HEK cells 
293T HEK cells are known to detach easily from plates. During the experiments, 
a difference between the numbers of cells in the wells, immediately after replacing the 
growth medium with diluted CSE medium was observed, thus generating a well-to-well 
error in the quantification of viable cells. An alternative was to apply coating agents to 
FCUP 
Analyzing the AOX potential as a prevention treatment for cigarette smoke 
26 
 
 
avoid of the loss of cells. In such conditions when the coating agents (gelatine and 
polylisine) were applied to the plates before seeding the cells a decrease in the amount 
of lost cells (visual estimation of approximately 30%) was observed, nonetheless the 
detachment of a considerable amount of cells upon replacing growth medium was still 
present in the assay, therefore all measurements performed had a well-to-well error.  
From several attempts made to perform the experiments, only one set of 
experiments, using polylysine coating treatment, produced a quality result where the loss 
of cells was consistent across all wells (visual estimation of approximately 10%-15%). In 
these experiments HEK cell lines were able to remain viable when incubated for 24h in 
CSE concentrations up to 30%. Number of viable cells decreasing with the increase in 
CSE concentration. Concentrations higher than 30% lead to the death of entire culture 
in both cell lines.  
Upon quantifying the number of viable cells after a CSE long-term incubation 
(24 h) in DMEM supplemented with 10% FBS (low glucose and galactose), no significant 
difference in the viable cell quantity between the AOX and WT cell lines was detected 
(p>0.05; Figures 17 and 18), thus suggesting that there is no difference in physiological 
response to CSE between AOX and WT. Due to the inability to eradicate or nullify the 
well-to-well error in the experiments, further testing with this cell line were stopped, in 
favour of other cell lines more adherent to the plate surface, such as fibroblast cell lines 
(MEFs and NIH 3T3). 
 
 
 
 
 
 
Figure 19 Results of HEK cells incubated in CSE dilutions in DMEM low glucose for 24 h in both number of thousands of 
viable cells (on the left) and ratio between live cells in tested condition and control condition with 0% CSE (on the right).  
 
DMEM Low Glucose 
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Figure 20 Results of HEK cells incubated in CSE dilutions in DMEM galactose for 24 h in both number of thousands of 
viable cells (on the left) and ratio between live cells in tested condition and control condition with 0% CSE (on the right).  
 
3.2.2- MEFs from Aox-Rosa26 
In the experiments performed with MEFs cell lines (both AOX and WT), cells were 
able to remain viable when incubated for 24 h in CSE-supplemented media with CSE 
concentrations up to 8%. Number of viable cells decreased with increasing 
concentrations of CSE. Concentrations higher than 8% lead to the death of entire culture 
in both cell lines. 
Upon quantifying the number of viable cells after a CSE long-term incubation 
(24 h and 48 h) in DMEM supplemented with 20% FBS (low glucose and galactose), no 
significant difference in the viable cells quantity between the AOX and WT cell lines was 
observed (p>0.05; Figures 19 and 20), thus suggesting that there is no difference in 
physiological response to CSE between AOX and WT. 
  
DMEM Galactose 
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Figure 21 Results of MEF cells incubated in CSE dilutions in DMEM high glucose for 48 h in both number of thousands 
of viable cells (on the left) and ratio between live cells in tested condition and control condition with 0% CSE (on the right). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 Results of MEF cells incubated in CSE dilutions in DMEM galactose for 48 h in both number of thousands of 
viable cells (on the left) and ratio between live cells in tested condition and control condition with 0% CSE (on the right). 
 
After the first set of experimental analysis, it was determined that higher amounts 
of FBS in the medium could eventually provide a protective effect to the cells from CSE, 
thus masking AOX protection. To assure that experimentally, a deadly blockade at the 
complex III level, was induced by overnight incubation of cell cultures in 20% FBS DMEM 
(high glucose) with 100 µM AMA. Both of the cell lines were able to remain viable after 
AMA exposure, as opposite to what was expected since AMA should have produced a 
DMEM High Glucose 
(20% FBS) 
N=4 
DMEM Galactose 
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lethal effect in the WT lines, which were unable to bypass the induced blockade. As a 
secondary validation, the same AMA treatment was performed using DMEM medium 
supplemented with 5% FBS (instead of 20% FBS). After the overnight incubation the, 
WT cell’s survival was greatly compromised in comparison to the AOX, which were still 
able to proliferate after removing the AMA.  
With this new data the same CSE incubation experiment was performed, using 
DMEM medium supplemented with 5% FBS to determine if the absence of a protective 
effect was indeed due to the high concentration of FBS. CSE concentration in which cells 
were able to remain viable was decrease to concentrations up to 5%, when comparing 
to the 8% CSE concentration in the previous CSE incubation experiments 
By quantifying the number of viable cells after a CSE long-term incubation of 24 h 
in DMEM (low glucose and galactose), no significant difference in the viable cells quantity 
between the AOX and WT cell lines was detected (p>0.05; Figures 21 and 22). Same 
result was observed with a CSE incubation of 48 h in DMEM galactose (p>0.05; 
Figure 23), thus suggesting that there is no difference in physiological response to CSE 
between AOX and WT.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 Results of MEF cells incubated in CSE dilutions in DMEM low glucose (5%FBS) for 24 h in both number of 
thousands of viable cells (on the left) and ratio between live cells in tested condition and control condition with 0% CSE 
(on the right). 
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Figure 24 Results of MEF cells incubated in CSE dilutions in DMEM galactose (5%FBS) for 24 h in both number of 
thousands of viable cells (on the left) and ratio between live cells in tested condition and control condition with 0% CSE 
(on the right). 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 Results of MEF cells incubated in CSE dilutions in DMEM galactose (5%FBS) for 48 h in both number of 
thousands of viable cells (on the left) and ratio between live cells in tested condition and control condition with 0% CSE 
(on the right). 
 
 
DMEM Galactose 
(5% FBS) 
N=4 
DMEM Galactose 
(5% FBS) 
N=2 
FCUP 
Analyzing the AOX potential as a prevention treatment for cigarette smoke 
31 
 
 
In order to analyse if the absence of a protective effect was due culture growth 
being desynchronized, a long term CSE incubation (48 h) with the addition of a 24 h 
DMEM 2% FBS incubation prior to CSE exposure, to synchronize the culture G0 phase 
by serum restriction(61), was performed. By quantifying the number of viable cells no 
significant difference in the viable cell quantity between the AOX and WT cell lines was 
detected (p>0.05; Figures 24), thus suggesting that there is no difference in physiological 
response to CSE between AOX and WT.  
 
 
 
 
 
 
 
 
 
 
Figure 26 Results of MEF cells incubated in CSE dilutions in DMEM galactose (5%FBS) for 48 h, with previous 24 h 
incubation in the same medium with 2% FBS, in both number of thousands of viable cells (on the left) and ratio between 
live cells in tested condition and control condition with 0% CSE (on the right). 
 
3.2.3- NIH 3T3 cells  
 Upon the generation NIH 3T3 (both AOX and WT), a long term CSE incubation 
for 24 h using DMEM supplemented with 10% CBS (low glucose and galactose) was 
performed. A long term CSE incubation for 48 h using DMEM supplemented with 
10% CBS (galactose) was also performed with and without culture synchronization by 
24 h incubation in  DMEM supplemented with 2% CBS before CSE exposure. 
By quantifying the number of viable cells after a 24 h CSE long-term incubation  
in DMEM (low glucose and galactose), no significant difference in the viable cells quantity 
between the AOX and WT cell lines was detected (p>0.05; Figures 25 and 26). Same 
result was also observed with a CSE long term incubation of 48 h in DMEM galactose, 
without and with the 2% CBS incubation (p>0.05; Figure 27 and 28), thus suggesting 
that there is no difference in physiological response to CSE between AOX and WT. 
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Figure 27 Results of NIH 3T3 cells incubated in CSE dilutions in DMEM low glucose for 24 h, in both number of thousands 
of viable cells (on the left) and ratio between live cells in tested condition and control condition with 0% CSE (on the right). 
 
 
 
 
 
 
 
 
Figure 28 Results of MEF cells incubated in CSE dilutions in DMEM galactose for 24 h, in both number of thousands of 
viable cells (on the left) and ratio between live cells in tested condition and control condition with 0% CSE (on the right). 
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Figure 29 Results of MEF cells incubated in CSE dilutions in DMEM galactose for 48 h, in both number of thousands of 
viable cells (on the left) and ratio between live cells in tested condition and control condition with 0% CSE (on the right). 
 
 
 
 
 
 
 
 
 
 
Figure 30 Results of MEF cells incubated in CSE dilutions in DMEM galactose for 48 h, with previous 24 h incubation in 
the same medium with 2% FBS, in both number of thousands of viable cells (on the left) and ratio between live cells in 
tested condition and control condition with 0% CSE (on the right). 
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4- Discussion 
 
In this work the first goal was to purify a catalytic active AOX protein in a 
heterologous system. Second goal was to test if AOX presence could be used to protect 
against cell damage caused by CSE. The combination of the results from both goals 
would provide a viable method to deliver a functional AOX inside the cells for medical 
treatment and data about AOX potential as an attenuation treatment of the cigarette 
smoke damage. Regarding the first goal, purified recombinant AOX from a bacterial 
extract was catalytically active and actively taken up by mammalian cells. On the second 
goal it was observed that AOX expression does not confer resistance to CSE. 
 
4.1- Recombinant AOX production 
Recent studies have provided promising results regarding the of AOX as a rescue 
treatment for patients with COX deficiencies (3, 4, 6), therefore the question of how to 
deliver a catalytically active AOX to patients’ cells was raised.  Both messenger 
ribonucleic acid (mRNA) and protein delivery to the intracellular space provide a 
temporary presence of the protein inside the cell, leading to no long-term concerns since 
the protein will eventually be turnover, and in the case of mRNA, the delivered sequence 
will be degraded over time preventing further expression of the protein. In this project the 
protein delivery method was chosen.  
In order to do so it was tested if a catalytically active recombinant AOX could be 
produced in heterologous systems and delivered to the respiratory chain of mammalian 
cells. 
 
4.1.1- Plasmid engineering 
In order to increase the yield of recombinant protein extracted, used engineered 
plasmids contained a SUMO protein sequence upstream of the AOX sequence, to 
prevent incorporation of the AOX protein in the bacterial mitochondrial membranes and 
increase its solubility in the cytosol. Furthermore, to improve the efficiency of transfection 
of the purified protein, an 11 amino acid TAT sequence was added in one of the set of 
plasmids. TAT conjugation should provide a direct import of the protein to the intracellular 
space(45) negating the need for a specific transfection treatment to the cells. TAT protein 
conjugation system was used to deliver Ndi1 to the mitochondria of mice heart cells(49, 
50), proving that its import does not compromise the mitochondrial import sequence. Also, 
in silico analysis of recombinant TAT-AOX sequence showed that TAT does not affect 
AOX’s mitochondrial import sequence. 
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4.1.2- Protein production  
Due to AOX being a mitochondrial membrane protein, it was expected that some 
of the amount of produced protein would be integrated into the membranes, despite the 
presence of the SUMO protein, the result of the protein production was challenging since 
most of the protein was being incorporated into the membrane. By decreasing the growth 
temperature, thus slowing down the growth rate as well as protein incorporation into the 
membrane, an increase of the amount of protein in the soluble fraction was achieved, 
this increase was higher when using the E. coli Rosetta 2 strain. Reasons behind the 
different results in E.coli strains are unknown, although it can be proposed that it was 
due to differences in some metabolic pathways taking in account that Roseta 2 are a 
derivate of BL21, designed to enhance the expression of eukaryotic proteins (55).  
When supplementing the medium with iron salts, due to the presence of a di-iron 
centre in one of the AOX subunits structure, an increase in the amount of protein in the 
membranes was observed. Knowing that the presence of the di-iron centre is crucial for 
the protein catalytic activity, it can be assumed that with a slower growth rate (30 °C), 
the iron integration, in native bacterial culture conditions, into the recombinant protein 
produced is lower. Therefore, the observed increased in the amount of the protein in its 
soluble form, might the soluble protein produced was not catalytically active. However, 
this latest fact did not give rise to any concern since the protein could receive the iron 
needed to be active inside the transfected cells, and if proven to be insufficient to be 
catalytically active, an iron supplementation of the protein could be facilitated by 
transferring the soluble protein to an iron enriched buffer.  
 
4.1.3- Protein purification 
Purification of recombinant AOX from the bacterial protein extract was successful 
on the first try, the inability to obtain a highly pure protein was expected by taking into 
consideration that a crude extract was used, further purifications with increased affinity 
for the HIS tag would be needed to produce a highly pure protein. 
Imidazole presence in the cleavage buffer proved to be a crucial addition to 
keeping the TAT-AOX protein soluble upon the removal of the SUMO protein, in the 
absence of imidazole in the buffer the samples corresponding to the cleavage protein 
showed no band both in the Western blot and in the SDS-page for the TAT- AOX, thus 
suggesting a loss of protein by precipitation. 
However despite the success in removing the SUMO protein and keeping the 
protein soluble, further purification of the protein in order to separate it from the cleaved 
SUMO protein and remaining bacterial proteins, proved unseccessful. Band 
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corresponding to TAT-AOX disappeared after being passed through the column 
suggesting that the protein was being trapped inside the column without the possibility 
of extracting it. Knowing that it is possible to purify trypanosomal AOX(62), and having 
access to a 3D structural model of the Ciona intestinalis AOX using Trypanosome AOX 
as a template for homology modelling (Figure 3), it is possible to extrapolate that the two 
extra highly charged loops in the Ciona intestinalis AOX might interact with the column 
matrix therefore trapping the protein inside the column. One solution to this problem may 
be to change or remove the matrix inside the column preventing the trapping of the TAT-
AOX.  
Using alternative production and purification methods such as an E. coli based 
cell free protein synthesis system with liposome supplementation might be a solution to 
producing a highly pure recombinant AOX. So far, this system has been successful for 
production of membrane proteins (category in which AOX is included) in soluble form 
without toxicity or inhibitory condition to the host. Integration into extracellular liposomes, 
allows a protein purification by targeting the liposomes (63), enhance providing a highly 
pure protein without unidentified bacterial proteins. 
 
4.1.4- TAT AOX activity assay 
In the in vitro assay by comparing the confluence reached between the controls, 
it was possible to observe that number of viable cells in the culture exposed to the TAT-
AOX was significantly less than the ones present in both the WT and AOX controls. 
Furthermore, concentrations of TAT-AOX higher than 0.027 µg/µL lead to the death of 
the entire culture, in a period less than 3 h.  
TAT protein deleterious role in the development and progression of HIV related 
neurodegenerative diseases has already been demonstrated in various studies(64, 65), 
furthermore  TAT toxicity in cell transfect assays has been observed with TAT 
concentrations of 100 µM or higher(66). Non-disregarding TAT cytotoxic role in cellular 
assays, in this work it was proposed that the unidentified bacterial proteins, present in 
the enriched TAT-AOX extract, were to some extent toxic to the culture. Therefore by 
using an ultra-pure TAT-AOX solution, no toxicity effects should be observed in 
mammalian cells. However, in the event of the observation of a toxicity effect with an 
ultra-pure TAT-AOX solution an alternative protein conjugation method, such as 
antennapedia conjugation(66, 67), could be employed to avoid toxic effects on cells. 
The observed toxicity of the enriched TAT-AOX extract could also be the reason 
for the low (less than 60%) TAT-AOX success of transfection observed in the exposed 
cells incubated with AMA. By comparing the physiological response to AMA incubation 
between WT and AOX cell lines, it is safe to conclude that only cells containing AOX 
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were able to remain viable, by performing a bypass of the lethal blockade caused by 
AMA. Therefore, it can be concluded that all cells exposed to TAT-AOX which were able 
to remain viable after AMA incubation, had been positively transfected with a catalytically 
active AOX. 
Western blot using protein extracts from the cells incubated with TAT-AOX was 
attempted, however no AOX was detected in the extract. Absence of AOX in the blot 
could be explained by many facts; such as the amount of protein used was considered 
small (less than 10 µg), the diluted amount of protein will not be completely removed 
from the medium by cellular uptake, by harvesting the cells there is always some protein 
loss due to cell undergoing apoptosis, the protein extract does not solubilize every single 
protein in the cells and lastly that the Western blot technique also has some protein loss 
associated to it in the blotting of the proteins from the SDS gel to the nitrocellulose 
membrane, therefore it was possible that amount of AOX protein was not enough to be 
detected.  
Time limitations allowed for only one replicate of the experiment, however taking 
in consideration both visual analysis as well as the quantification of viable cells we have 
strong evidence that the TAT-AOX was incorporated and catalytically active. Further 
activity assays with an inactive TAT-AOX (such catalytically inactive AOX mutant) serving 
as a negative control, complemented with antibody staining of the cells might help to 
support this evidence showing method allows an effective delivery of a catalytically active 
AOX to mammalian cells.  
To analyse the incorporation and catalytic activity of the enriched TAT-AOX 
extract in mammal tissues, it was asked the help of Natascha Sommer’s laboratory to 
perform an ex vivo assay, using a perfused mouse lung. According to her readout, TAT-
AOX was positively incorporated into the lung cells and was catalytically active. 
Furthermore, by analysing the results provided it was possible to observe that perfusion 
of a WT mouse lung under hypoxic challenge, with a TAT-AOX diluted physiological 
buffer, successfully blunted the high value in pressure gradient, thus correlating with the 
physiological behaviour of AOX heterozygous lung. Obtained ex-vivo results, suggests 
that the delivery system has the potential to work in an in vivo assay, however due to the 
limitations of an ex-vivo assay, endocrine and immunity systems responses to the 
presence of TAT-AOX were not evaluated.  
Despite the promising result, such ex-vivo assays requires the use of a 
catalytically inactive TAT-AOX, to validate the readout that the neutralization of the 
hypoxia pressure was related to the incorporation of a catalytically active AOX and not 
to the perfusion of the lung with a protein supplemented physiological buffer.  
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4.2- AOX protection against CSE damage 
 
From the more than 5000 hazards components in CS(11), cyanide and carbon 
monoxide are known inhibitors of complex IV, furthermore it has been shown that 
cigarette smoke is able to cause a deadly blockade in the respiratory chain and shifting 
the cell death mechanism from apoptosis to necrosis(36). This is due to a depletion of ATP 
inside the cell which makes the cell unable to withstand the energy required to undergo 
apoptosis. Taking into account previous data, it could be drawn a conclusion that if the 
blockade is bypassed and the ATP production maintained, by using an alternative 
oxidase such as AOX with the ability to bypass blockades in the cytochrome part of the 
respiratory chain(38), cells may be protected against CS damage. To test this hypothesis 
three different AOX cell lines with their respective WT controls were used.  
 
4.2.1- 293T HEK cells 
In the experiments using the 293T HEK cells, a well-to-well error was associated 
with all the quantification performed. This was due to the cells easy detach from the 
plates surfaces, at room temperature, with a little pressure or harsh handling conditions. 
Polylysine coated plates, proved to be effective in decreasing the well-to-well error, but 
unable to prevent it. Therefore, for technical reasons the data collected cannot be used 
to reach any conclusions regarding the protective effect of AOX. Optimization of the 
experiments set up with the ability to quantify the detached number of cells in each step 
of medium replacement, would provide a way to normalize all readings thus reducing the 
well-to-well error associated with the quantification assay.  
 
4.2.2- MEFs from Aox-Rosa26 
MEFs cell lines were produced by Praveen from AOXRosa26 mice. Briefly, mice 
were generated by a site-directed integration of Ciona intestinalis AOX into the 
ROSA26(68) locus via homologous recombination, where a strong and ubiquitous CAG 
promoter controls its expression (unpublished data). AOX protein was expressed 
ubiquitous in all tissues (unpublished data). Despite its high expression level, AOX had 
no obvious adverse effect on the general mouse phenotype or expression levels of other 
mitochondrial respiratory chain subunits (unpublished data). AOX RNA expression was 
analyzed by Northern blotting which correlated with the protein expression levels. Where 
expressed, AOX confers respiratory resistance to azide and AMA (unpublished data).  
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Initially, cells were grown in medium containing 20% FBS, thus it was decided to 
use the same growth condition for the assays with a long term CSE incubation (48 h). 
CSE concentrations in which cells were able to remain viable, were shown to be much 
lower in the MEFs than in the 293T HEK, although the reason for such was not 
scrutinised as the two cell lines were physiologically different and thus different 
intracellular conditions and metabolism were most likely the cause. 
Due to the absence of a significant difference in physiological response between 
the AOX cells and their respective WT to CSE incubation, it was hypothesized that the 
cause could be the protective effect that FBS plays in the growth medium(69). With the 
thought that it was neutralizing or blocking the effect of the compounds that caused a 
deadly blockade by interacting with the respiratory chain, therefore preventing AOX to 
confer any protection since the damage was not being caused at the respiratory chain 
level. Validation of this hypothesis with AMA incubation, resulted in a decrease of the 
FBS concentration in the medium to 5%. Both 24 h and 48 h CSE incubation showed to 
have no difference in physiological response between AOX cells and their respective WT 
control, thus indicating that the presence of AOX was not able to protect the cells against 
CSE damage.  
Successive lack of a protective AOX effect in experiments performed with both 
293T HEK and MEFs cell lines, led reconsidering the experimental design. A synchronize 
the cells in G0 phase, an incubation step with a restrictive serum concentration for 24 h 
was performed followed by a 48 h long term CSE incubation. In these set of experiments 
only galactose medium was tested, as AOX copes with a high reduction of the respiratory 
chain. By using growth conditions that favour OXPHOS respiration the possible 
difference in physiological response between cell lines, would be increased. The 
obtained results showed that the presence of AOX does not provide any protection 
against CSE damage, enabling to exclude the hypothesis that the protective AOX effect 
could have been masked by the desynchronized growth of the cultures.  
Taking into account that there were unpublished preliminary results obtained by 
Manish Kumar, a collaborator researcher in a laboratory in Bad Nauheim, showing that 
the presence of AOX conferred some protection against CSE damaged in NIH 3T3 cell 
lines, it was decided to repeat the experimental approach used for MEFs in NIH 3T3 cells 
to corroborate the obtained MEFs results or to show that for some unknown reason the 
cells were not behaving as fibroblast cells. 
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4.2.3- NIH 3T3 cells 
Due to some technical problems, NIH 3T3 AOX cell lines needed to be produced 
anew, thus the number of replicates of each experiment was not higher than two. Results 
obtained for a 24 h CSE incubation, both low glucose and galactose medium showed no 
significant difference in physiological response between the AOX cells and their 
respective WT controls. Same result was observed for the 48 h CSE incubation in 
galactose medium, with and without a culture growth synchronization by serum 
restriction. Lethal CSE concentration for the NIH 3T3 cell was similar to one for MEFs. 
Obtained with the NIH 3T3 cells corroborate those obtained with the previous tested cell 
lines, leading to three possible conclusions.  
First, was that based solely on the results obtained in this work, the problem lay 
not in the experiment but in the concept that it tries to prove showing that AOX might be 
unable to prevent any damage caused by CSE, therefore not having any protective effect 
on the cells against CS damage.  
Second, was that the produced CSE might not be the same standard CSE used 
when producing the preliminary results, resulting in a loss, either by neutralization or 
volatilization, of some key components that interact with the respiratory chain such as 
cyanide which is highly unstable under cell culture conditions(70). Therefore maintaining 
the CSE deadly effect due to the other thousands of compounds solubilized in the 
medium, but preventing AOX protection due to the inexistence of a blockade in the 
cytochrome chain.  
The last possible conclusion was that although there were some preliminary data 
that AOX protects the cells from CSE damage, at this point, for some unclear reason, 
the cells behaved differently in both works. Thus making it unable to determine if AOX 
might have potential applications for protecting cells against CS damage, without further 
studies in the subject. 
In order to be able to determine which is the correct conclusion the most efficient 
option would be to ask to a collaborating laboratory, experienced in CSE assays, to 
replicate the results obtained in this work. In doing so it, would provide a comparison of 
the produced CSE as a validation of either the results obtained in this work or the 
preliminary results of AOX protective effect in NIH 3T3 cells. Further steps can also be 
taken by testing not only cell viability but also other physiological processes such as 
apoptosis versus necrosis ratio, proliferation and autophagy. 
However, considering the limitations of using CSE, which mostly contains the 
aqueous soluble components of CS, testing CSE exposure alone is not enough. Further 
studies using alternatives toxins extraction methods, such as cigarette smoke 
condensate (CSC) production by collecting the particulated phase the CS in a filter and 
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diluting in dimethyl sulfoxide (DMSO)(71), or even direct smoke exposure using ‘whole 
smoke exposure systems’(72),  should be performed before reaching any conclusions 
regarding potential AOX clinical applications in CS health issues. 
 
 
4.3- Conclusion  
 
The use of alternative enzymes to attenuate mitochondrial disease phenotypes 
is a growing field with many possible applications. In this work it was attempted to purify 
a recombinant AOX that could be delivered to the respiratory chain of mammalian cells 
while retaining its catalytic activity, as well as to analyse the use of AOX as a protective 
treatment against CS damage. 
Production and purification of a recombinant AOX was achieved. Further 
optimization of the process will provide a highly pure recombinant protein. Strong 
evidence, both in vitro and ex vivo, regarding recombinant protein catalytic activity and 
ability to transfect cells were presented in this work. Upon validation, clinical applications 
using the recombinant AOX can be tested in in vivo systems.  
Results obtained in this work suggest that AOX does not confer protection against 
CSE damage. Further studies in the subject are needed to conclude about AOX clinical 
applications in CS health issues. 
Summarising this work provided a protocol to produce a catalytically active AOX 
in heterologous systems and scientific data about the use of AOX to confer protection 
against CS.  
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